Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodevelopmental Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PAK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAK1 Active Kinase / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic assays. |
View PAK1 Products |
| Gene Delivery | PAK1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and rescue assays. |
View PAK1 Products |
| Benchmark Ab | Anti-PAK1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View PAK1 Products |
| Validator | PAK1 siRNA Set For knockdown verification and phenotype validation. |
View PAK1 Products |
| Related Target A | PAK2 Critical counter-screening target to evaluate off-target toxicity and selectivity. |
View PAK2 Products |
| Related Target B | RAC1 Upstream activator of PAK1; key node in GTPase-mediated signaling. |
View RAC1 Products |
| Related Target C | CDC42 Upstream Rho GTPase regulator triggering PAK1 autophosphorylation. |
View CDC42 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against highly homologous PAK2 | High-purity, sequence-verified Recombinant PAK1 and PAK2 proteins available for parallel IC50 screening. |
| Allosteric vs. ATP-competitive screening | Both full-length and kinase-domain-only constructs available to differentiate binding mechanisms. |
| Lack of Controls | Validated reference small molecules and biosimilar tool antibodies included. |
| False Positives | Sequence-specific siRNA sets included for target knockdown validation. |
Live PAK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PAK1 therapeutics is intensifying, with major players shifting focus from traditional ATP-competitive pan-PAK inhibitors to highly selective allosteric inhibitors and PROTAC degraders. As first-generation therapies reach the clinic, the next wave of R&D is targeting isoform-specific signaling nodes to minimize dose-limiting toxicities associated with systemic PAK2 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Small Molecules | Karyopharm, Preclinical Biotech | Solid Tumors (Breast, Pancreatic), Neurofibromatosis | Selectivity Assay (Need high-purity PAK1 vs. PAK2 proteins) |
| PROTAC Degraders | Academic Institutions, Early-stage Biotechs | Colorectal Cancer, Drug-resistant Melanoma | Target Engagement & Degradation (Need Lentivirus for stable reporter lines) |
| Combination Therapies | Oncology Consortia | KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) | Synergy Validation (Need RAC1/CDC42 pathway controls) |